These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 25548497

  • 1. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.
    World J Gastroenterol; 2014 Dec 21; 20(47):17976-84. PubMed ID: 25548497
    [Abstract] [Full Text] [Related]

  • 2. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.
    Health Technol Assess; 2006 Nov 21; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [Abstract] [Full Text] [Related]

  • 3. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
    Tse VC, Ng WT, Lee V, Lee AW, Chua DT, Chau J, McGhee SM.
    BMC Cancer; 2011 Jul 09; 11():288. PubMed ID: 21740590
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.
    Lancet Oncol; 2012 Dec 09; 13(12):1225-33. PubMed ID: 23168362
    [Abstract] [Full Text] [Related]

  • 5. Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.
    Xie Q, Wen F, Wei YQ, Deng HX, Li Q.
    Colorectal Dis; 2013 Aug 09; 15(8):958-62. PubMed ID: 23506229
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.
    Cancer; 2007 Mar 15; 109(6):1082-9. PubMed ID: 17265519
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z.
    Pharmacoeconomics; 2014 Mar 15; 32(3):235-43. PubMed ID: 23709451
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
    Tan C, Peng L, Zeng X, Li J, Wan X, Chen G, Yi L, Luo X, Zhao Z.
    PLoS One; 2013 Mar 15; 8(12):e83396. PubMed ID: 24340099
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.
    Pharmacoeconomics; 2009 Mar 15; 27(7):597-608. PubMed ID: 19663530
    [Abstract] [Full Text] [Related]

  • 10. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.
    Value Health; 2011 Mar 15; 14(5):647-51. PubMed ID: 21839401
    [Abstract] [Full Text] [Related]

  • 11. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F, Schrag D, Kuntz KM.
    Value Health; 2022 Mar 15; 25(3):409-418. PubMed ID: 35227453
    [Abstract] [Full Text] [Related]

  • 12. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
    Cancer; 2012 Jun 15; 118(12):3173-81. PubMed ID: 22020739
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
    Wu B, Li T, Cai J, Xu Y, Zhao G.
    BMC Cancer; 2014 Dec 19; 14():984. PubMed ID: 25526802
    [Abstract] [Full Text] [Related]

  • 14. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A.
    JAMA Netw Open; 2020 Oct 01; 3(10):e2020425. PubMed ID: 33074326
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.
    Value Health; 2012 Oct 01; 15(2):255-60. PubMed ID: 22433756
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
    Shiroiwa T, Fukuda T, Tsutani K.
    Br J Cancer; 2009 Jul 07; 101(1):12-8. PubMed ID: 19491895
    [Abstract] [Full Text] [Related]

  • 17. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Tran G, Hack SP, Kerr A, Stokes L, Gibbs P, Price T, Todd C.
    Asia Pac J Clin Oncol; 2013 Sep 07; 9(3):239-48. PubMed ID: 23279720
    [Abstract] [Full Text] [Related]

  • 18. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.
    Br J Cancer; 2006 Apr 24; 94(8):1122-9. PubMed ID: 16622438
    [Abstract] [Full Text] [Related]

  • 19. [Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].
    Büchler T, Nohejlová Medková A, Kupec M, Bláha M, Pavlík T, Dušek L, Abrahámová J.
    Klin Onkol; 2012 Apr 24; 25(6):440-4. PubMed ID: 23301646
    [Abstract] [Full Text] [Related]

  • 20. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.
    Lancet Oncol; 2014 Dec 24; 15(13):1481-1492. PubMed ID: 25456367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.